The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

Mr. Ajay Tandon
Managing Director
Veeda Clinical Research Limited

"Our Values define who we are as Veedaites and represent the minimum standards of behaviour that will be expected of us by anyone that we engage with, be it our colleagues, clients, volunteers, business partners, shareholders or any other stakeholders."

Read More

Partners in Creating

a healthier tomorrow

Veeda News
Update on our webinar and upcoming panel discussion

Regulatory
Industry wants FDA to align visible particle classifications and inspections with USP

Financial
Why Pharma MNCs Are Realigning Their India Operations

Clinical Research
Trends in Decentralized Clinical Trial Remote Monitoring for Medication Adherence

Merger and Acquisition
Mankind Pharma to acquire two brands from Dr Reddy's Laboratories

Indian Pharma
India to grow fastest among large nations in FY23

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

Webinar on Bioanalytical aspects of BA/ BE studies for Endogenous Molecule

Here's the webinar recording for you!



Our Director - Medical and Regulatory Affairs, Dr. Kiran Marthak will be participating at the 5th Pharma Regulatory Summit 2022

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

Moving forward on goal to boost local pharmaceutical production, WHO establishes global biomanufacturing training hub in Republic of Korea

The World Health Organization (WHO), the Republic of Korea and the WHO Academy today announced the establishment of a global biomanufacturing training hub that will serve all low- and middle-income countries wishing to produce biologicals, such as vaccines, insulin, monoclonal antibodies and cancer treatments. The move comes after the successful establishment of a global mRNA vaccine technology transfer hub in South Africa.

Read More

European medicines regulatory network adopts EU common standard for electronic product information

The European Medicines Regulatory Network has adopted a Common Standard for the electronic product information (ePI) on medicines in the European Union (EU). This will pave the way for wider dissemination of the unbiased, up-to-date information on all medicines available to patients in the EU through an ever-expanding range of electronic channels.

Read More

Industry wants FDA to align visible particle classifications and inspections with USP

Drugmakers and pharmaceutical industry groups urged the US Food and Drug Administration (FDA) to align its classification categories for visible particles with the US Pharmacopoeia's (USP) Chapter 1790 in comments on the agency's recent draft guidance on inspection of injectable products for visible particulates. One international group asserted that "different definitions lead to different interpretations,".

Read More

WHO launches new guideline for the control and elimination of human schistosomiasis

The World Health Organization (WHO) has launched a new guideline1 that provides evidence-based recommendations to countries in their efforts to achieve control and elimination of schistosomiasis as a public health problem, and to move towards interruption of transmission. "The main aim is to provide evidence-based recommendations to countries to eliminate schistosomiasis as a public health problem and to move towards interruption of transmission," said Dr Amadou Garba Djirmay, who leads the global programme for the control and elimination of schistosomiasis.

Read More

Ensuring artificial intelligence (AI) technologies for health benefit older people

Geneva: Artificial intelligence (AI) technologies have the potential to improve older people's health and well-being, but only if ageism is eliminated from their design, implementation, and use. A new policy brief, Ageism in artificial intelligence for health, released today by the World Health Organization (WHO) presents legal, non-legal and technical measures that can be used to minimize the risk of exacerbating or introducing ageism through these technologies.

Read More

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

NPPA cancels RFP to study pricing policy of 10 countries; fixes retail price of 19 formulations

The National Pharmaceutical Pricing Authority (NPPA) has cancelled a recent Request for Proposal (RFP) floated to conduct the study on drug pricing policies of different countries, regions and lessons learnt from these countries and regions in terms of access to medicine at affordable prices. The Authority said that its decision to cancel the RFP is due to “administrative exigencies”.

Read More

A € 500 million pledge under the WHO – EIB partnership, with the support of the EU, for health systems in Africa

Dr Tedros Adhanom Ghebreyesus, WHO Director-General, met today with Werner Hoyer, President of the European Investment Bank (EIB), to discuss the WHO-EIB initiative aiming at promoting an innovative impact investment that will support health systems strengthening in Africa with a focus on Primary Health Care (PHC). A joint statement was released. WHO welcomed the new EIB commitments to support impact investing, in the context of a new tripartite initiative (WHO-EIB- European Commission), established to support countries across Africa to close the health funding gap.

Read More

More than 172.25 crore Covid vaccine doses administered in India: Govt

he cumulative number of Covid-19 vaccine doses administered in the country crossed 172.75 crore on Saturday, the Union health ministry said. More than 44 lakh vaccine doses were administered till 7 pm on Saturday, the ministry said, adding that the daily vaccination tally is expected to go up with the compilation of the final reports by late night.

Read More

The week that was: Solara Active Pharma shines amid broader selling

The last week was a weak one for the stock market as most sectors were under selling pressure. Critical conditions at the Russia-Ukraine border and rising inflation continued to dictate proceedings on Dalal Street. In the BSE500 index, nearly 125 stocks ended the week with gains while the rest recorded losses. “In absence of any major event, the focus would remain on the Russia-Ukraine tension and its impact on global markets. Besides, the scheduled monthly expiry of February month derivatives contracts would further add to the choppiness.

Read More

Why Pharma MNCs Are Realigning Their India Operations

Earlier this month, Swiss drug major Novartis India sold its three established brands to Dr Reddy’s Laboratories and terminated the employment of 400 staffers. In October, US drugmaker Eily Lily sold the marketing rights of its anti-diabetes drugs to Cipla and laid off 120 employees in India. Around the same time, Danish pharma company Lundbeck decided to exit India as part of its global strategy. In 2019, US drug major Pfizer closed two facilities manufacturing injectables in the country in response to falling demand.

Read More

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

Trends in Decentralized Clinical Trial Remote Monitoring for Medication Adherence

Today in clinical research and development, the patient has become the priority. The processes of accessing clinical trial information and participating in clinical trials need to be simple and easy. In recent years, there has been a lot of talk about patient-centricity and patient engagement. These are no longer just idle words; they have become the ecosystem through which pharmaceutical companies develop and deliver new life-saving drugs, and technology is just the conduit to help pharma do this.

Read More

Parexel, Medidata extend decentralized clinical trial partnership

The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies. Medidata, a Dassault Systèmes company, has announced that it and clinical research organization (CRO) Parexel are extending their strategic partnership, which has gone on for 15 years prior to now. The collaboration will work toward “pioneering a new era of decentralized clinical trial technology.” Additionally, Parexel participates in Medidata’s Early Adopter DCT program, which leverages the myMedidata patient portal, Sensor Cloud, and Medidata’s proprietary Patient Centricity by Design program.

Read More

Helping Clinical Trial Sites Improve Study Recruitment and Retention

The clinical trial industry is, once again, at an uncertain crossroads. And while it might be assumed that the outsized impact of the COVID-19 pandemic has resulted in the inability to recruit patients for trials, it is instead, a challenge generated, over time, by the industry itself. Thankfully, there is an opportunity to change course. It’s no secret that research studies and clinical trial sites struggle with recruitment. In fact, the National Institutes of Health (NIH) states that of all terminated clinical trials, 55 percent were terminated due to low accrual rates. In total, around 80 percent of research studies fail to meet their enrollment goals in their projected timeframes.

Read More

Clinical Trials Regulation Now Applicable - Careful, When It Comes to IP

The Clinical Trials Regulation entered into application on 31 January 2022. It praises itself to ensure a favourable environment for clinical research on a large scale in the EU, with high standards of public transparency and safety for clinical trial participants. On 31 January 2022, the Regulation repealed the Clinical Trials Directive (EC) No. 2001/20/EC and national implementing legislation in the EU Member States, which regulated clinical trials in the EU.

MAIWALD INTELLECTUAL PROPERTY

Read More

India now prime destination for big pharma's global clinical trials

A new set of rules in place since 2019 is beginning to make India an attractive destination for big pharma to conduct clinical trials in India. These rules have brought India's regulatory framework on par with U.S. Food and Drug Administration (FDA) norms and now India is among the top choices for global clinical trials, industry experts say. "India is among top five destinations for our clients while choosing clinical trial sites and numerous big global studies are now being carried out in India," Sanjay Vyas, managing director - India and global SBU head.

Read More

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

Taro Pharmaceutical to acquire Alchemee from Galderma

Taro Pharmaceutical Industries Ltd has agreed to purchase Alchemee, previously The Proactiv Company (TPC), from Galderma. The deal involves Alchemee's entire business and assets all over the world, including the Proactiv brand. “We are proud of the work we have done together to serve customers suffering from acne around the world through Proactiv. I am confident that Taro is the right owner to build on Alchemee's strong foundation.

Read More

Recipharm Acquires Two Biologics CDMOs: Vibalogics and Arranta Bio

Recipharm announced on Feb. 18, 2022 that it has acquired Vibalogics and Arranta Bio, both contract development and manufacturing organizations (CDMOs), expanding its manufacturing capabilities in the virotherapy and advanced therapy spaces, respectively. Vibalogics, a virotherapy CDMO and a portfolio company of Ampersand Capital Partners, has been making it presence known in the biopharma industry by providing specialized CDMO services for the manufacture of live viruses and viral vectors, including herpes viruses, pox viruses, adenoviruses, and other viral classes for cancer and other applications.

Read More

Binnopharm Group inks deal to acquire two anti-bacterial brands from Dr. Reddy’s in the Russia & CIS region

Binnopharm Group, one of the leading pharmaceutical production companies in Russia, has signed a deal with Dr. Reddy’s Laboratories to acquire its anti-bacterial medicines under the Ciprolet and Levolet brands in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops. The Sistema Group company Binnopharm Group has signed the deal via its affiliate Joint Stock Company ‘Alium’.

Read More

Mankind Pharma to acquire two brands from Dr Reddy’s Laboratories

Mankind Pharma on Wednesday said it has inked a pact with Dr Reddy’s Laboratories to acquire two brands — Combihale and Daffy. While Combihale is used for the treatment of asthma and chronic obstructive pulmonary disease, Daffy is a soap-free moisturising bar for infants Mankind Pharma said the market for Combihale is valued at Rs 900 crore growing at 14 per cent. The acquisition of the product is expected to strengthen the company’s presence in the inhalation respiratory market segment, Mankind Pharma said in a statement.

Read More

Warburg Pincus’ Acquisition of Pharma Intelligence

Warburg Pincus, a leading global growth investor, on the acquisition of Pharma Intelligence, a leading provider of specialist intelligence, data, and software for clinical trials, drug development, and regulatory compliance, from Informa PLC (LSE: INF.L), the international B2B markets knowledge services and business intelligence group. Mubadala Investment Company, the Abu Dhabi based investment company, joins Warburg Pincus in the investment.

Read More

veeda clinical research

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

How the Indian Pharmaceutical Industry is planning to grow in 2022

Contributing immensely to global health, the Indian pharmaceutical industry by volume is the 3rd largest in the world. In (2021-2022) FY22, the pharmaceutical industry recorded a growth of 9-11 per cent which was mainly driven by a push from emerging and domestic markets. By showing strength and commitment amid the disruption caused by the pandemic, the industry not only exhibited its ability to provide adequate medicines but contributed significantly to other areas like sanitation, preventive healthcare and quarantine facilities.

Read More

Indian pharma's next chapter of growth depends on innovation and R&D investments

The global pharma industry has witnessed an exponential development and growth in the last few decades. With the advent of COVID-19 in 2020, the industry has experienced a quantum jump to become a resilient pillar of the economy. The global pharma market had marked a total revenue of $1,112.6 billion in 2020, indicating a Compound Annual Growth Rate (CAGR) of 5.6 per cent between 2016 and 2020. As one of the largest contributors, our domestic pharma sector has also shown a considerable increase in growth of around 15 per cent in the last year.

EXPRESS PHARMA

Read More

How the pandemic led to the emergence of a new, promising market for refurbished devices in India

Is old the new cool, I wondered when I was at a small mobile shop to get my phone repaired. A couple had walked into that store to purchase a new iPhone as they wanted to upgrade their older version. But they didn't choose a brand new phone; they opted for a refurbished one available at a price much lower than a new one. I kept thinking there would be some defect or damage, but the couple was categorical that they wanted to upgrade to a new phone without investing much and that it would help their child in online classes.

Read More

India to grow fastest among large nations in FY23

With the third wave subsiding and vaccination numbers fast approaching the final target, India will clock the quickest pace among large nations in FY23 with growth being steady across sectors, the finance ministry's department of economic affairs has said in its monthly economic report. "In a testimony to the resilience of its people and the farsightedness of its policymaking, the Indian economy that contracted by 6.6 percent in 2020-21 is now projected in 2022-23 to grow the quickest among the league of large nations," the report said.

Read More

M&A deal value in healthcare and related sectors grows 58% pushed by pharma and API deals in 2021

The Mergers and Acquisitions (M&A) deals in the healthcare and related sectors have experienced a higher growth at 58.4 per cent in terms of value during the year 2021, with the major push coming from pharma and active pharmaceutical ingredients (API) products and hospitals and clinics segments. The year 2021 saw 72 deals happening of which value of 39 deals were announced at a cumulative $3.74 billion as compared to a total of 51 deals of which value of 32 were announced as $2.36 billion during the year 2020, according to data from Venture Intelligence, a research service focused on private company financials, transactions and their valuations.

Read More

The Veeda Newsletter

FEBRUARY 2022: ISSUE 02

For any further information or Business enquiry contact us at info@veedacr.com

ADDRESS:

Corporate Office

VEEDA CLINICAL RESEARCH LIMITED
Block 6, Magnet Corporate Park,
100 ft. Thaltej - Hebatpur Road,
Nr.Sola Bridge, Off. S.G.Highway,
Thaltej, Ahmedabad 380 054

Registered Office

Shivalik Plaza-A, Near IIM Ambawadi,
Ahmedabad- 380015, Gujarat, India.
CIN No. U73100GJ2004PTC044023

OTHER ADDRESS:

- Sarkhej - Gandhinagar Highway
  Vedant Complex, S. G. Highway, nr. YMCA club,
  Ahmedabad, Gujarat 380051

- Insignia, Besides Auda Garden, Opp. Zenobia
  Residency, Sindhu Bhavan Road, Off. S. G. Highway,
  Bodakdev, Ahmedabad- 380059, Gujarat, India

- Radhe Palladium
  Panchot Cir, Kunal, Mehsana, Gujarat 384002